# SETHY (NCT07068542)

> Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07068542
- Phase: NA
- Status: RECRUITING
- Sponsor: Zhejiang Provincial People's Hospital
- Conditions: Advanced Thyroid Carcinoma; Radioiodine-refractory Differentiated Thyroid Cancer; Poorly Differentiated Thyroid Carcinoma
- Interventions: Sacituzumab Tirumotecan (SKB264) plus Tislelizumab; Sacituzumab Tirumotecan (SKB264)
- Enrollment: 94
- Primary outcome: Overall Survival (OS) - ATC Cohort
- Primary outcome: Progression-Free Survival (PFS) - PDTC and RAIR-DTC Cohorts

## Indexed commentary on SETHY so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 9

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=sethy-nct07068542

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT07068542", "email": "<work email>"}; the inbox owner confirms by the emailed link.